Thus, we observed a reduced PP2A activity in all the five breast cancer cell lines analyzed, identifying PP2A hyperphosphorylation and SET and CIP2A overexpression in all cases, which prompted us to hypothesize that these could be relevant contributing mechanisms to inhibit PP2A in breast cancer. This evidence concerns the gene SET and breast carcinoma.